AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39379797
Drug: Standard Treatment
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Treatment (low-fat diet and lifestyle modification)
Trial: 39379845
Drug: iCBT Shyness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iCBT Shyness Program (internet-delivered cognitive-behavioral therapy)
Trial: 39379877
Drug: Suicide Attempts
RxNorm normalized name: modified Ankara virus-mediated suicide gene delivery vector TG4023
DrugBank: TG4023 (DB06108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suicide Attempts Multi-component Intervention Treatment (SAMIT) - 8 sessions of individual psychotherapy combining Dialectical Behaviour Therapy (DBT), Mentalization-Based Therapy (MBT), and Narrative approaches.
Trial: 39379877
Drug: Treatment-as-usual intervention
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual intervention (TAU)
Trial: 39379885
Drug: Treatment difference
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment difference between BTC and NLED
Trial: 39379931
Drug: Lazertinib 240
RxNorm normalized name: lazertinib 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazertinib 240 mg/day
Trial: 39380086
Drug: Community-wide mass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-wide mass drug administration (cMDA) with 400 mg albendazole
Trial: 39380954
Drug: Patient-specific dosimetry
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-specific dosimetry for DTC patients receiving radioiodine (RAI) therapy
Trial: 39380967
Drug: Pyrotinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib (400 mg once daily) and capecitabine (1000 mg/m2)
Trial: 39381777
Drug: Multimodal sensor-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal sensor-based eHealth intervention during 14 video sessions of cognitive-behavioral therapy (CBT)
Trial: 39381863
Drug: Pegunigalsidase alfa
RxNorm normalized name: Pegunigalsidase alfa
DrugBank: Pegunigalsidase alfa (DB14992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegunigalsidase alfa 2 mg/kg every 4 weeks for 52 weeks
Trial: 39382244
Drug: Remote daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote daily multidisciplinary rounds led by a board-certified intensivist through telemedicine, monthly audit and feedback meetings, provision of evidence-based clinical protocols.
Trial: 39382244
Drug: Telemedicine intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telemedicine intervention (daily multidisciplinary rounds).
Trial: 39382241
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (transfusion triggered by hemoglobin <9 g/dL; n=408)
Trial: 39382241
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (transfusion triggered by hemoglobin <7 g/dL; n=442)
Trial: 39382446
Drug: First-line anti-angiogenesis
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line anti-angiogenesis therapy
Trial: 39382446
Drug: Second-line anti-angiogenesis
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line anti-angiogenesis therapy
Trial: 39382587
Drug: Control (G-C)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (G-C)
Trial: 39383026
Drug: Preoperative acupuncture;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative acupuncture; details on dosage and duration not available
Trial: 39383382
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma and standard treatment
Trial: 39383612
Drug: Second-line immunosuppressants
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line immunosuppressants (SLI)
Trial: 39383771
Drug: naporafenib plus
RxNorm normalized name: Naporafenib
DrugBank: Naporafenib (DB18865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naporafenib plus rineterkib (naporafenib 400 mg BID, rineterkib 200 mg QD)
Trial: 39383771
Drug: naporafenib plus
RxNorm normalized name: Naporafenib
DrugBank: Naporafenib (DB18865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naporafenib plus trametinib (naporafenib 200 mg BID, trametinib 1 mg QD)
Trial: 39383771
Drug: naporafenib plus
RxNorm normalized name: Naporafenib
DrugBank: Naporafenib (DB18865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naporafenib plus trametinib (naporafenib 400 mg BID, trametinib 0.5 mg QD)
Trial: 39384067
Drug: Cendakimab 360
RxNorm normalized name: Cendakimab
DrugBank: Cendakimab (DB18427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cendakimab 360 mg once weekly for 48 weeks
Trial: 39384067
Drug: Cendakimab 360
RxNorm normalized name: Cendakimab
DrugBank: Cendakimab (DB18427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cendakimab 360 mg once weekly for 24 weeks followed by cendakimab 360 mg every other week for 24 weeks (with matching placebo on alternative weeks)
Trial: 39384067
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once weekly for 48 weeks
Trial: 39384087
Drug: Benzoate 1000
RxNorm normalized name: benzoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzoate 1000 mg/day
Trial: 39384087
Drug: Benzoate 500
RxNorm normalized name: aminobenzoate 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzoate 500 mg/day
Trial: 39384087
Drug: Benzoate 750
RxNorm normalized name: imidazole-2-hydroxybenzoate 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzoate 750 mg/day
Trial: 39384194
Drug: BMS-986156 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-986156 (30 mg) with ipilimumab (3 mg/kg)
Trial: 39384194
Drug: BMS-986156 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-986156 (100 mg) with ipilimumab (3 mg/kg)
Trial: 39384194
Drug: BMS-986156 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-986156 (30 mg) with nivolumab (480 mg) and SABR
Trial: 39384241
Drug: CAS+IMD 1200
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAS+IMD 1200 mg
Trial: 39384241
Drug: CAS+IMD 2400
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAS+IMD 2400 mg
Trial: 39384241
Drug: CAS+IMD (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAS+IMD (1200 mg or 2400 mg)
Trial: 39384342
Drug: eGFR <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR < 60 mL/min/1.73m²
Trial: 39384342
Drug: eGFR <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR < 90 mL/min/1.73m²
Trial: 39384451
Drug: Olaparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (300 mg b.i.d.) + Abiraterone (1000 mg o.d.) + Prednisone (5 mg b.i.d.)
Trial: 39384451
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Abiraterone (1000 mg o.d.) + Prednisone (5 mg b.i.d.)
Trial: 39384609
Drug: MGTA-145 (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGTA-145 (0.03 mg/kg) intravenously with plerixafor subcutaneously
Trial: 39384614
Drug: Intranasal human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal human milk (IHM) therapy
Trial: 39384712
Drug: Dapagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (10 mg/day) with standard medical therapy (Group A)
Trial: 39384712
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with standard medical therapy (Group B)
Trial: 39385217
Drug: OD(-) group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OD(-) group (withdrawal of life-sustaining therapies without planned organ donation)
Trial: 39385217
Drug: OD(+) group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OD(+) group (withdrawal of life-sustaining therapies with planned organ donation)
Trial: 39385279
Drug: Concussion-focused cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concussion-focused cognitive behavioral therapy (cf-CBT)
Trial: 39385279
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cf-CBT, PST, and CM
Trial: 39385327
Drug: Abemaciclib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib plus non-steroidal aromatase inhibitor (anastrozole or letrozole)
Trial: 39385523
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel 1.62% (40.5 mg/day for 16 weeks)
Trial: 39385523
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel 1.62%
Trial: 39385595
Drug: Citrulline Malate
RxNorm normalized name: CITRULLINE MALATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrulline Malate (6 g)
Trial: 39385595
Drug: Placebo (6 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (6 g of corn starch)
Trial: 39385752
Drug: Hexavalent vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexavalent vaccine (DTaP-IPV-HB-Hib)
Trial: 39385752
Drug: Pentavalent vaccine
RxNorm normalized name: rotavirus, live, pentavalent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavalent vaccine (DTwP-HB-Hib)
Trial: 39386177
Drug: High-dose Tacrosolv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Tacrosolv (5 µg tacrolimus/eye/day)
Trial: 39386444
Drug: Neoadjuvant endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant endocrine therapy with letrozole
Trial: 39386444
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy (letrozole)
Trial: 39387403
Drug: Other disease-modifying
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other disease-modifying antirheumatic drugs
Trial: 39387441
Drug: Asciminib (oral),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asciminib (oral), dose-escalation in second-line treatment
Trial: 39387441
Drug: Asciminib (oral),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asciminib (oral), dose-escalation in first-line treatment
Trial: 39387766
Drug: Renin-angiotensin system
RxNorm normalized name: Renin-angiotensin system inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin-angiotensin system inhibitor (RASi)
Trial: 39389076
Drug: MVA-MERS-S vaccine
RxNorm normalized name: MVA-SARS-2-S
DrugBank: MVA-SARS-2-S (DB16432)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-MERS-S vaccine (10^8 PFU) administered intramuscularly in three doses at 28-day intervals
Trial: 39389081
Drug: VIR-2218 200
RxNorm normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIR-2218 200 mg subcutaneously every 4 weeks (cohort 1)
Trial: 39389081
Drug: VIR-2218 200
RxNorm normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIR-2218 200 mg subcutaneously every 4 weeks plus pegylated interferon-alfa-2a (cohort 2)
Trial: 39389081
Drug: VIR-2218 200
RxNorm normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIR-2218 200 mg subcutaneously every 4 weeks plus pegylated interferon-alfa-2a (cohort 3)
Trial: 39389081
Drug: VIR-2218 200
RxNorm normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIR-2218 200 mg subcutaneously every 4 weeks plus pegylated interferon-alfa-2a (cohort 4)
Trial: 39389081
Drug: VIR-2218 200
RxNorm normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIR-2218 200 mg subcutaneously every 4 weeks plus pegylated interferon-alfa-2a (cohort 5)
Trial: 39389081
Drug: VIR-2218 200
RxNorm normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIR-2218 200 mg subcutaneously every 4 weeks plus pegylated interferon-alfa-2a (cohort 6)
Trial: 39389081
Drug: VIR-2218 200
RxNorm normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIR-2218 200 mg subcutaneously every 4 weeks
Trial: 39389599
Drug: Blood and
RxNorm normalized name: BLOOD AND RELATED PRODUCTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood and biological samples (plasma and saliva) collected during treatment
Trial: 39390132
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg bevacizumab-800CW
Trial: 39390132
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg bevacizumab-800CW
Trial: 39390228
Drug: Newly restored
RxNorm normalized name: Restone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newly restored implant (PICF)
Trial: 39390362
Drug: Wait-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait-list control group (maintained usual activity, received monthly health education talk)
Trial: 39390398
Drug: COVID-19 mRNA
RxNorm normalized name: COVID-19 mRNA vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 mRNA booster vaccine
Trial: 39390583
Drug: MIPD dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIPD dosing calculator for AUC-based dosing with extra sampling for therapeutic drug monitoring
Trial: 39390760
Drug: White button
RxNorm normalized name: button mushroom extract
DrugBank: Cultivated mushroom (DB10544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White button mushroom (WBM) treatment
Trial: 39390760
Drug: White button
RxNorm normalized name: button mushroom extract
DrugBank: Cultivated mushroom (DB10544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White button mushroom (WBM) tablets for 3 months
Trial: 39392161
Drug: Protocolized intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Protocolized intervention pathway activated by high-risk scores; nurse-implemented uptitration of diuretic for 4 days
Trial: 39392467
Drug: Low-load blood
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-load blood flow restriction exercise (BFRE) at 40% total arterial occlusion pressure, using 30-40% of 1-repetition maximum loads, conducted twice weekly for two weeks
Trial: 39392616
Drug: Algorithm-based mobile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm-based mobile texting platform delivering 4 treatment modules (education and behavioral modification, cognitive behavioral therapy, pelvic floor physical therapy, guided mindfulness practices) and an automated weekly message over 6 weeks
Trial: 39393045
Drug: IV natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV natalizumab Q6W dosing
Trial: 39393045
Drug: IV natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV natalizumab Q4W dosing
Trial: 39393045
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of Q6W vs Q4W dosing
Trial: 39393084
Drug: 60-mg admilparant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-mg admilparant
Trial: 39393084
Drug: 30-mg admilparant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-mg admilparant
Trial: 39393528
Drug: Opioid-free anesthesia
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid-free anesthesia (OFA) with sevoflurane-dexmedetomidine, continuous infusion of lidocaine and ketamine, and magnesium sulfate during induction
Trial: 39393528
Drug: Opioid-sparing anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid-sparing anesthesia (OSA) with sevoflurane-sufentanil boluses and continuous infusion of lidocaine
Trial: 39393777
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus chemotherapy (±bevacizumab)
Trial: 39393777
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus chemotherapy (±bevacizumab)
Trial: 39393844
Drug: Allogeneic bone
RxNorm normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic bone marrow mesenchymal stromal cells (BM-MSCs) - 20 million cells via intradiscal injection
Trial: 39393844
Drug: Sham placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham placebo injection
Trial: 39394158
Drug: CR +
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CR + BWLT (12 weekly, group-based virtual sessions, followed by 12 weeks of follow-up support)
Trial: 39395139
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care services (medication reconciliation, medication review, patient education)
Trial: 39395230
Drug: SARS-CoV-2 mRNA
RxNorm normalized name: SARS-CoV-2 mRNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 mRNA vaccination (specific dosage and duration not mentioned)
Trial: 39395231
Drug: FAP-IL2v 10
RxNorm normalized name: AVA-6000 (FAP-activated doxorubicin prodrug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAP-IL2v 10 mg administered once every 3 weeks (Q3W) or once weekly (QW) for 4 weeks then once every 2 weeks (Q2W) with corresponding atezolizumab regimens.
Trial: 39395266
Drug: Fruquintinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib monotherapy
Trial: 39395266
Drug: Fruquintinib combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib combined with chemotherapy and/or anti-PD-1 antibodies
Trial: 39395411
Drug: Anti-PD-1 plus
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 plus chemotherapy (combo)
Trial: 39395424
Drug: Standard-of-care (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care (oral PrEP and PEP)
Trial: 39395655
Drug: Garetosmab (anti-activin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garetosmab (anti-activin A antibody)
Trial: 39395753
Drug: Standard-dose inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose inactivated influenza vaccine (IIV4)
Trial: 39395964
Drug: Conventional dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dosage reduction
Trial: 39396529
Drug: Denifanstat 50
RxNorm normalized name: Denifanstat
DrugBank: Denifanstat (DB17576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denifanstat 50 mg once per day for 52 weeks
Trial: 39396702
Drug: High-dose DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose DHA supplementation
Trial: 39396760
Drug: Low-protein control
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein control meal (5 g protein)
Trial: 39396987
Drug: Celiac plexus
RxNorm normalized name: Bos taurus solar plexus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiac plexus block (anesthetic and steroid combination injected into the celiac plexus)
Trial: 39396991
Drug: Internet-delivered Cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered Cognitive Behavioral Therapy (iCBT) with planned feedback
Trial: 39396991
Drug: Internet-delivered Cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered Cognitive Behavioral Therapy (iCBT) with on-demand feedback
Trial: 39397156
Drug: Cumulative intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative intake >150 ml/kg MOM ± DHM within 7-10 days PNA
Trial: 39397784
Drug: Prime-2-CoV_Beta vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prime-2-CoV_Beta vaccine (orf virus-based multi-antigen COVID-19 vaccine)
Trial: 39398317
Drug: Anti-IgE therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-IgE therapy (omalizumab)
Trial: 39398317
Drug: Anti-IL-5/5R therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-IL-5/5R therapy
Trial: 39398317
Drug: Anti-IL-4R therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-IL-4R therapy
Trial: 39399770
Drug: Preoperative subacromial
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative subacromial injection of bupivacaine and epinephrine